Acrylic Acid And Derivatives Patents (Class 424/487)
-
Patent number: 8663688Abstract: Semisolid mucoadhesive formulations for vaginal application, with improved technical and organoleptic characteristics, which contain at least two bioadhesive gelling polymers and an active ingredient, useful in the prevention and/or treatment of various pathologies and disorders in human beings or animals.Type: GrantFiled: July 16, 2004Date of Patent: March 4, 2014Assignee: ITF Research Pharma, S.L.U.Inventors: Álvaro Acebrón Fernández, Ana Campuzano Garcia, Rosa Maria Hernández Martin, Manuela Igatúa Olaechea, José Luis Pedraz Muñoz, Alicia Rodriguez Gascón
-
Patent number: 8663689Abstract: A bioadherent substrate includes a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from a Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.Type: GrantFiled: February 19, 2010Date of Patent: March 4, 2014Assignee: Sofradim ProductionInventors: Sebastien Ladet, Philippe Gravagna
-
Patent number: 8663687Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least one active agent, which may be administered to a user topically, transmucosally, vaginally, ocularly, aurally, nasally, transdermally or orally.Type: GrantFiled: May 13, 2010Date of Patent: March 4, 2014Assignee: MonoSol Rx, LLCInventors: Garry L. Myers, Richard C. Fuisz
-
Patent number: 8658207Abstract: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.Type: GrantFiled: August 13, 2007Date of Patent: February 25, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Wolfram Eisenreich, Thomas Friedl, Florian Sommer, Nantharat Pearnchob, Karl G. Wagner
-
Patent number: 8658146Abstract: The present invention relates to a water-absorbing composition comprising water-absorbing polymer structures, on the surface of which is at least one tannin fraction which has a number-average molecular weight, determined in accordance with the test method described herein, of at least 1,000 g/mol, which has a weight-average molecular weight, determined in accordance with the test method described herein, of at least 1,000 g/mol, or which is a hydrolysable gallotannin. The present invention also relates to a process for the preparation of a water-absorbing composition, the water-absorbing composition obtainable by this process, a composite, a process for the production of a composite, the composite obtainable by this process, chemical products, such as, for example, hygiene articles, the use of a water-absorbing composition or of a composite and the use of a tannin fraction.Type: GrantFiled: September 24, 2008Date of Patent: February 25, 2014Assignee: Evonik Degussa GmbHInventors: Franck Furno, Laurent Wattebled, Anne Ix-Mund, Harald Schmidt, Markus Henn, Jorg Harren
-
Patent number: 8658711Abstract: Methods for synthesizing a methacrylate-derivatized type-I collagen in which methacrylic acid is reacted with a carboxylic acid activating reagent in the presence of a carbodiimide to form a methacrylic acid with an activated carboxylic acid group, which is then reacted with free amino groups on type-I collagen to form a collagen methacrylamide. Methacrylate-derivatized collagen, cross-linked collagens formed therefrom and products containing the cross-linked collagen are also disclosed.Type: GrantFiled: September 29, 2011Date of Patent: February 25, 2014Assignee: Rutgers, The State University of New JerseyInventors: David Shreiber, Ian Gaudet
-
Patent number: 8653004Abstract: Process for producing actives-comprising polymeric networks from oligomers containing (meth)acrylate groups, optionally from further monomers, and from actives, the polymeric networks obtainable by the process, and the use of the networks for various purposes, more particularly for protecting materials or in crop protection.Type: GrantFiled: July 25, 2008Date of Patent: February 18, 2014Assignee: BASF SEInventors: Alexandre Terrenoire, Hartmut Leininger, James Bullock, Mohammed Shoaib Qureshi, Hans-Werner Schmidt, Reiner Giesa, Meik Ranft, Oscar Lafuente Cerda
-
Patent number: 8647672Abstract: The invention relates to an implant material comprising a polymer which is partially cross-linked by means of a metal acrylate salt.Type: GrantFiled: September 20, 2010Date of Patent: February 11, 2014Assignee: AAP Biomaterials GmbHInventors: Oliver Bielenstein, Stefan Deusser, Christoph Sattig, Volker Stirnal
-
Patent number: 8642087Abstract: Antioxidant polymeric compounds are provided that comprise a plurality of monomeric portions, where each monomeric portion includes an antioxidant molecule interposed between at least two acrylate molecules, and where at least one acrylate molecule of each monomeric portion is linked by a diamine molecule to an acrylate molecule of an adjacent monomeric portion to thereby form the polymer. Methods of synthesizing polymeric compounds and methods of using the antioxidant polymeric compounds to reduce oxidative stress are also provided.Type: GrantFiled: November 7, 2011Date of Patent: February 4, 2014Assignee: University of Kentucky Research FoundationInventors: Thomas D. Dziubla, J. Zach Hilt, Dipti Biswal, David B. Cochran, Paritosh P. Wattamwar
-
Patent number: 8642089Abstract: The invention relates to a method for producing active ingredient-containing granules or powders involving the following steps: a) melting a mixture consisting of a pharmaceutical active ingredient and of a (meth)acrylate copolymer, which is comprised of 40 to 75 wt. % of radically polymerized C1 to C4 alkyl esters of acrylic acid or of methacrylic acid and can be comprised of 25 to 60 wt. % (meth)acrylate monomers having an anionic group in the alkyl radial; b) extruding the mixture, and; c) comminuting the extrudate to form a granule or powder. The inventive method is characterized in that the active ingredient is the salt of an alkaline substance, and in that the pH value, which can be measured on the obtained powder or granule, is equal to or less than pH 7.0. The invention also relates to pharmaceutical dosage forms or precursors thereof, which can be produced using the inventive method.Type: GrantFiled: January 30, 2003Date of Patent: February 4, 2014Assignee: Evonik Roehm GmbHInventors: Hans-Ulrich Petereit, Christian Meier, Andreas Gryczke
-
Patent number: 8629197Abstract: A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the hydrogel. The chemically patterned modified hydrogel is formed by exposing the modified hydrogel to multiphoton excitation to deprotect a portion of the protected groups.Type: GrantFiled: April 7, 2008Date of Patent: January 14, 2014Inventors: Molly Shoichet, Jordan Wosnick, Ryan Wylie
-
Patent number: 8623409Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.Type: GrantFiled: October 20, 2010Date of Patent: January 7, 2014Assignee: Tris Pharma Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8609131Abstract: An absorbent dressing is described which comprises a crosslinked hydrophilic gel absorbent layer comprising a first component polymer comprising a plurality of polymerized monomer units having pendent hydrophilic groups, and pendent Michael donor groups; and a crosslinking agent comprising at least two Michael acceptor groups.Type: GrantFiled: January 25, 2005Date of Patent: December 17, 2013Assignee: 3M Innovative Properties CompanyInventors: David J. Plaut, Duane D. Fansler, Kevin M. Lewandowski, Babu N. Gaddam
-
Patent number: 8586087Abstract: An amphiphilic pentablock copolymer that is temperature- and pH-sensitive and has superior and sustained gel strength, includes (a) a hydrophilic triblock copolymer that is temperature-sensitive and that is a copolymer of a poly(ethylene glycol)-based compound and a biodegradable polymer that is one or more polymer selected from the group consisting of polylactide, polyglycolide, polycaprolactone, poly(caprolactone-lactide) random copolymer, poly(caprolactone-glycolide) random copolymer, poly(lactide-glycolide) random copolymer, and mixtures thereof; coupled with (b) a polyurethane-based oligomer (PU) that is pH sensitive and that includes a diisocyanate compound represented by a Formula as follows: OCN—(CH2)n—NCO, where n is an integer of 4 to 10, polymerized with a diol compound having a tertiary amine on a main chain thereof that is one or more of 1,3-bis{1-(2-hydroxyethyl) -4-pyridyl}propane and 1,4-bis(2-hydroxyethyl)piperazine, and is represented by Formulae as follows: where R and R? are alkyl grouType: GrantFiled: April 2, 2008Date of Patent: November 19, 2013Assignee: Sungkyunkwan University Foundation for Corporate CollaborationInventors: Doo Sung Lee, Kasala Dayananda, Bong Sup Kim
-
Patent number: 8586088Abstract: Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.Type: GrantFiled: December 18, 2012Date of Patent: November 19, 2013Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
-
Patent number: 8580830Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.Type: GrantFiled: October 2, 2007Date of Patent: November 12, 2013Assignees: Labtec GmbH, APR Applied Pharma Research S.A.Inventors: Christian Leichs, Armin Breitenbach, Ingo Lehrke, Paolo Galfetti
-
Patent number: 8580302Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.Type: GrantFiled: March 3, 2005Date of Patent: November 12, 2013Assignee: Warner Chilcott Company, LLCInventors: Gregory Paul Dittmar, Joseph Michael Amante, Tony Ryan Cronk, Daniel Gary Newby
-
Patent number: 8568778Abstract: The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients.Type: GrantFiled: November 5, 2005Date of Patent: October 29, 2013Assignee: Evonik Röhm GmbHInventors: Rosario Lizio, Hans-Ulrich Petereit, Dave Trupti, Michael Gottschalk
-
Publication number: 20130273162Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapuetic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.Type: ApplicationFiled: April 12, 2012Publication date: October 17, 2013Inventor: Michael Hsin Chwen LI
-
Patent number: 8545886Abstract: The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable pH-independent polymers; d) one or more pharmaceutically acceptable acids; and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.Type: GrantFiled: August 13, 2007Date of Patent: October 1, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Wolfram Eisenreich, Thomas Friedl
-
Patent number: 8535728Abstract: Colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described. The composition can be incorporated into a hydrogel with essentially no loss of antimicrobial properties.Type: GrantFiled: June 3, 2004Date of Patent: September 17, 2013Assignee: American Silver, LLCInventors: Robert J. Holladay, Herbert Christensen, William Moeller
-
Patent number: 8524256Abstract: The disclosure relates to a deodorant composition comprising a physiologically acceptable water-in-oil emulsion carrier comprising at least one antiperspirant ingredient and at least one semicrystalline polymer having a melting point greater than or equal to 30° C. The disclosure further relates to the use of cosmetic products for topical application to humans, such as deodorant products, and to methods of treating human perspiration and body odors associated with human perspiration. This composition may be in the form of a cosmetic cream having a very pleasant texture on application to the skin.Type: GrantFiled: June 24, 2004Date of Patent: September 3, 2013Assignee: Air Products and Chemicals, Inc.Inventors: Estelle Prud'Homme, Véronique Douin
-
Patent number: 8524368Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.Type: GrantFiled: December 14, 2011Date of Patent: September 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Adam D. Miller
-
Patent number: 8524273Abstract: A transdermal absorption preparation having a support and a pressure-sensitive adhesive layer consisting of multiple layers, wherein the pressure-sensitive adhesive layer comprises a drug-retaining layer containing a drug and an acrylic pressure-sensitive adhesive and a skin adhesion layer containing a styrene-isoprene-styrene block copolymer. This preparation can continuously release bisoprolol at a constant concentration. Moreover, it can be easily produced.Type: GrantFiled: February 27, 2007Date of Patent: September 3, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Satoshi Amano, Sachiko Honma, Tetsuro Tateishi, Natsumi Kase
-
Patent number: 8524759Abstract: An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine.Type: GrantFiled: July 9, 2012Date of Patent: September 3, 2013Inventor: Douglas J. Gordon
-
Patent number: 8507527Abstract: The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.Type: GrantFiled: February 25, 2010Date of Patent: August 13, 2013Assignee: EISAI R & D Management Co., Ltd.Inventors: Yosuke Ueki, Yasuyuki Suzuki, Satoshi Fujioka
-
Patent number: 8501215Abstract: Injectable depot compositions are provided that include a polymer matrix having a plurality of bioerodible, biocompatible polymers wherein each polymer of the plurality of polymers has a specified average molecular weight, and the polymer matrix has a broad molecular weight distribution of the plurality of polymers; a solvent having a miscibility in water of less than or equal to 7 wt % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith; and a beneficial agent. The compositions have substantially improved shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.Type: GrantFiled: July 28, 2003Date of Patent: August 6, 2013Inventors: Guohua Chen, Paul Houston, Lothar Kleiner, Jeremy Wright
-
Patent number: 8497357Abstract: A heterobifunctional poly(ethylene glycol) is provided having a hydrolytically degradable linkage, a first terminus comprising an acrylate group, and a second terminus comprising a target such as a protein or pharmaceutical agent or a reactive moiety capable of coupling to a target. Hydrogels can be prepared. The hydrogels can be used as a carrier for a protein or a pharmaceutical agent that can be readily released in a controlled fashion.Type: GrantFiled: April 13, 2012Date of Patent: July 30, 2013Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Xuan Zhao
-
Publication number: 20130189333Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: ALTRIA CLIENT SERVICES INC.Inventor: Altria Client Services Inc.
-
Patent number: 8491935Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.Type: GrantFiled: November 1, 2012Date of Patent: July 23, 2013Assignee: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8481071Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: May 29, 2012Date of Patent: July 9, 2013Assignee: Corium International, Inc.Inventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bairamov
-
Patent number: 8481565Abstract: The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.Type: GrantFiled: December 27, 2005Date of Patent: July 9, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Yosuke Ueki, Yasuyuki Suzuki, Satoshi Fujioka
-
Publication number: 20130171256Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.Type: ApplicationFiled: May 9, 2011Publication date: July 4, 2013Applicant: CIMA LABS Inc.Inventor: Ehab Hamed
-
Patent number: 8475837Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.Type: GrantFiled: November 23, 2010Date of Patent: July 2, 2013Assignee: Teikoku Pharma USA, Inc.Inventors: Carter R. Anderson, Russell L. Morris
-
Patent number: 8475844Abstract: Polymers of fluorinated monomers and acrylate and alkyl acrylates are disclosed which demonstrate improved performance as coatings for implantable devices. Such coatings may, for example, be used to release a bioactive agent from the medical device. One specific application lies in drug-eluting coatings for stents.Type: GrantFiled: April 16, 2009Date of Patent: July 2, 2013Assignee: Boston Scientific Scimed, Inc.Inventors: Gordon Kocur, David Rolf, James Lasch, Kasyap Seethamraju
-
Patent number: 8470905Abstract: A method and a device for effecting the cordless retraction of the gingival sulcus tissue that includes a dam shaped to be fitted onto a tooth. In one embodiment, the well of the dam is pre-filled with a predetermined amount of a flowable retraction material having a heavy viscosity or putty consistency. In another embodiment a hydrophilic material is added. The preloaded tooth dam is fitted to a prepared tooth so that when pressure is applied onto the tooth dam, the retraction material is displaced under pressure and forced into the sulcus, causing the gingival tissue to retract away from the tooth to enlarge the gingival sulcus. In another embodiment the cap is filled with a dilatant material. In another embodiment, the cap is filled with an impregnated compressible porous material. In yet another embodiment, the cap is pre-dosed with an astringent or hemostatic agent.Type: GrantFiled: May 15, 2011Date of Patent: June 25, 2013Assignee: Centrix, Inc.Inventors: William B. Dragan, John J. Discko
-
Publication number: 20130142877Abstract: The invention relates to a pharmaceutical dosage form comprising one or more antiretroviral active ingredients in the form of a solid dispersion or solid solution in a matrix, wherein said matrix comprises an amino(meth)acrylate copolymer, characterized in that the matrix does not contain any essential amounts of pharmaceutically acceptable surfactants with an HLB value from 12 to 18 and in that the matrix comprises a mono carboxylic acid or an alcohol with 12 to 22 carbon atoms or both.Type: ApplicationFiled: March 3, 2011Publication date: June 6, 2013Applicant: EVONIK ROEHM GmbHInventors: Pravin Nalawade, Smitha Shetty, Hema Ravishankar, Shripad Gadhinglajkar, Andreas Gryczke, Hans-Ulrich Petereit, Kathrin Nollenberger
-
Publication number: 20130129827Abstract: The present invention relates to extended release pharmaceutical compositions of paliperidone and process of preparation thereof.Type: ApplicationFiled: October 18, 2010Publication date: May 23, 2013Applicant: RANBAXY LABORATORIES LIMITEDInventors: Kumaravel Vivek, Rajan Kumar Verma, Romi Barat Singh
-
Patent number: 8445016Abstract: The invention features grafted polymer systems for use in medical devices and/or for the delivery of active agents. The grafted polymers include at least one transport moiety, a linear backbone segment, and a pendant segment.Type: GrantFiled: April 13, 2007Date of Patent: May 21, 2013Assignee: Interface Biologics, Inc.Inventors: J. Paul Santerre, Roseita Esfand, Meilin Yang
-
Patent number: 8440217Abstract: A contact lens product, a method and system for forming the contact lens product, and a method of using the contact lens product. The contact lens product includes a soft disposable contact lens loaded with a drug and the carriers which carry the drug. The lens has a mechanical and optical structure formed by the core polymer included within the lens. The contact lens product is configured to have the drug released from its carrier continuously into an eye of a mammal while the contact lens product is adhered to the eye of the mammal during a continuous period of time, the drug being configured to treat or prevent at least one adverse condition of the eye of the mammal during the continuous period of time. The mammal may be a human being or a veterinary animal.Type: GrantFiled: June 15, 2005Date of Patent: May 14, 2013Inventors: Mawaheb M. El-Naggar, Shaker A. Mousa
-
Patent number: 8436083Abstract: A coating having an adhesive hydrophilic polymer and an amphiphilic additive. The amphiphilic additive has a hydrophilic chain, a biocidal functional group bonded to the hydrophilic chain, and a hydrophobic moiety bonded to the hydrophilic chain or to the biocidal functional group. A method of forming a biocidal surface by providing an article, and coating the article with the above coating. A compound having the formula: Y—(O—CH2—CH2)n—R—(CH2)m—CH3. Y is CH3 or H. R is X is a halogen, and m and n are independently selected positive integers.Type: GrantFiled: January 7, 2008Date of Patent: May 7, 2013Assignee: The United States of America, as represented by the Secretary of the NavyInventors: James H Wynne, Joanne M Jones-Meehan, Arthur W Snow, Leonard J Buckley
-
Patent number: 8431143Abstract: A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in which a pharmaceutical compound is bound to titanium dioxide having photocatalytic activity through a hydrophilic polymer. The composite is stable in an aqueous solvent and easily administered into a living body, and adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the body and irradiating the composite with a light to photoexcite the titanium dioxide to decompose the pharmaceutical compound in a region where the drug efficacy of the pharmaceutical composition is not required.Type: GrantFiled: September 24, 2010Date of Patent: April 30, 2013Assignee: Toto Ltd.Inventors: Shuji Sonezaki, Koki Kanehira, Yumi Ogami, Toshiaki Banzai, Yoshinobu Kubota
-
Patent number: 8425925Abstract: Pesticidal compositions and articles providing topical application of a mixture of (1) a macrolide of the avermectin/milbemycin class, such as, but not limited to ivermectin, abamectin, or milbemectin, and (2) a synergist of the aryl aliphatic ether-class, such as, but not limited to piperonyl butoxide, present in (3) a weight ratio of synergist:macrolide that is great than 1:1. The compositions and articles demonstrate efficacy, even in point-of-contact applications, against various pests of domestic animals, such as, but not limited to arthropod ectoparasites including horn flies and buffalo flies. Methods are provided in which compositions can be employed as pour-ons, spot-ons, dusts, or sprays for direct topical application to the domestic animal; or in which articles comprising a polymer resin base, such as an ear tag, from which the active ingredients of the composition can be released, are affixed to the animal to provide long-term delivery.Type: GrantFiled: March 5, 2008Date of Patent: April 23, 2013Assignee: Y-Tex CorporationInventor: Joe D. Kellerby
-
Patent number: 8420121Abstract: Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO2 in the environment of the hydrogel are described. The drug delivery vehicles include hydrogels that swell or shrink in response to changes in the partial pressure of CO2 in their environment, thus regulating release of an entrapped drug.Type: GrantFiled: July 28, 2010Date of Patent: April 16, 2013Assignee: University of MassachusettsInventor: Sankaran Thayumanavan
-
Patent number: 8414923Abstract: A method for the immobilization of bioactive molecules within a polymer substrate to be employed as an oral drug delivery system is provided. A water insoluble carrier matrix can be provided that is water swellable, and biologically active agents can be incorporated. The matrix can be a macromolecular network synthesized by gamma radiation at temperatures between ?78 degrees Celsius to a boiling point of a component elected for polymerization.Type: GrantFiled: September 12, 2008Date of Patent: April 9, 2013Inventors: Eduardo Esteban Smolko, Eduardo Antonio Lombardo, Fabio Martin Lombardo, Jorge Héctor Lombardo
-
Patent number: 8404277Abstract: A matrix-type transdermal drug delivery system including capsaicin or a capsaicin derivative as an active component and used for treating neuropathy, pain, and inflammation and a preparation method thereof are provided. The matrix-type transdermal drug delivery system includes: a drug protecting layer; a matrix layer formed on the drug protecting layer and including 0.1-25 wt % of capsaicin or a capsaicin derivative, 40-95 wt % of an adhesive including a water-insoluble acrylic polymer, 1-30 wt % of an alcohol having a molecular weight of 600 Daltons or less, 0.1-20 wt % of a nonionic surfactant, and 0.1-20 wt % of a solubilizing agent including a hydrophilic polymer; and a release liner formed on the matrix layer, and is used for treating neuropathy, pain, or inflammation.Type: GrantFiled: June 5, 2008Date of Patent: March 26, 2013Assignee: Samyang Biopharmaceuticals CorporationInventors: Jin-Deok Song, Dong-Won Kim
-
Publication number: 20130059007Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.Type: ApplicationFiled: November 1, 2012Publication date: March 7, 2013Applicant: TRIS PHARMA, INC.Inventor: Tris Pharma. Inc.
-
Patent number: 8388984Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.Type: GrantFiled: September 14, 2011Date of Patent: March 5, 2013Assignees: Da Volterra, Centre National de la Recherche Scientifique, Assistance Publique—Hopitaux de Paris, Universite Paris Diderot—Paris 7, Universite Paris-SUD 11Inventors: Helene-Celine Huguet, Antoine Andremont, Nicolas Tsapis, Elias Fattal
-
Patent number: 8372933Abstract: Hyperbranched, water-soluble polymers, obtainable by Michael polyaddition of ?-, ?-, or ?-cyclodextrins and amines to bisacrylamides.Type: GrantFiled: June 10, 2008Date of Patent: February 12, 2013Assignee: L'Urederra Fundacion Para el Desarrollo Tecnologico y SocialInventors: Paolo Ferruti, Elisabetta Ranucci, Francesco Trotta, Roberta Cavalli, Claudio Fernandez
-
Patent number: 8357399Abstract: Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.Type: GrantFiled: July 9, 2012Date of Patent: January 22, 2013Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox